Neurodegenerative Drugs: Market Research Report

Date: April 22, 2010
Pages: 1108
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N56BC8F5362EN
Leaflet:

Download PDF Leaflet

Neurodegenerative Drugs: Market Research Report
This report analyzes the worldwide markets for Neurodegenerative Drugs in US$ Million by the following disease types: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Neurodegenerative Diseases.

The report provides separate comprehensive analytics for the US, Europe, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 165 companies including many key and niche players such as Amarin Corporation PLC, AstraZeneca PLC, Avanir Pharmaceuticals, Inc., Avigen, Inc., Bayer Schering Pharma AG, Boehringer Ingelheim GmbH, Biogen Idec Inc., Bristol-Myers Squibb Co., Biovail Corporation, Ceregene, Inc., Eisai, Inc., Elan Pharmaceuticals, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Merck Serono SA, Mitsubishi Tanabe Pharma Corporation, Neurologix, Inc., NeuroSearch A/S, Novartis AG, Pfizer, Inc., Sanofi-aventis S.A, Shire Pharmaceuticals Group PLC, Teva Pharmaceutical Industries Limited, Valeant Pharmaceuticals International, and Wyeth Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Others
Huntington’s Disease
Neuropathic Pain
Prion Disease

II. EXECUTIVE SUMMARY

1.GLOBAL MARKET OVERVIEW

Global Market Analysis
Global Market Analysis by Disease Type
Neurodegenerative Drugs – The Next Big Thing in Healthcare
Alzheimer’s and Parkinson’s Market
Factors Affecting the Market
Major Growth Drivers Ahead
Major Growth Inhibitors
Rapid Growth of Aging Population

Table 1. Global 65+ Age Group Population in Millions (includes corresponding Graph/Chart)

Higher Alzheimer’s and Parkinson’s Prevalence
Price Hikes and Government Caps
Future Holds Promise!
Research & Development
Neuroscience Research Focused on Neurodegenerative Diseases
Neuroscience Research Advances to Make a Mark…
Summary of Major Neuroscience Research Developments in 2009

2.A REVIEW OF SELECT NEURODEGENERATIVE DRUGS MARKETS

A. Alzheimer’s Market in Review
The AD Epidemiology

Table 2. World Alzheimer’s Disease Prevalence by Country/Region: Number of Patients in US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain and Rest of Europe), Asia-Pacific (Australia, India, Philippines and Rest of Asia-Pacific), Brazil and Rest of World in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)
Table 3. Alzheimer’s Disease Statistics in Top Seven Countries (US, Japan, Germany, France, UK, Italy and Spain): Number of Patients Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

The Impact of Dementia
A Look At AD Demographics
A Global Overview
Geographic Overview
Growth Drivers
Aging Baby Boomers - The Market’s Growth Engine

Table 4. AD Frequency Rates in the US and Europe: Percentage Share by Age Group (includes corresponding Graph/Chart)

Unmet Medical Needs Drive Market Growth
Growth Restrains
Misdiagnosis
Lack of Awareness
High Cost of Treatment
Market Outlook for Anti-AD Drugs
Cholinesterase Inhibitors – The Leader, but Not Strong Growth Contender
NMDA Receptor Antagonists – Dynamic Growth Potential, Albeit A Small Base
Approval of Anti-AD Drugs (Cholinesterase Inhibitors) in Select Countries
Competitive Landscape
B. The Parkinson’s Market in Review
The PD Epidemiology

Table 5. World Parkinson’s Disease Prevalence by Country/Region: Number of Patients in the US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain and Rest of Europe), China and Rest of World in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

A Global Overview
Dominance of Dopamine Agonists
Stalevo Continues to Outshine
The Slippery Path to Clinical Success
Market Drivers
Emergence of Dopamine Agonists as First Line Treatment
The Debut of Stalevo
High Unmet Clinical Needs
Market Inhibitors
Lack of Awareness and Under-diagnosis
Limitations of Existing Medicines
Restricted Period Use of Dopamine Agonists
Generic Competition from L-Dopa and Carbidopa
C. The Multiple Sclerosis Market in Review
The MS Epidemiology

Table 6. World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

Facts About Multiple Sclerosis
Market Overview
Interferon-based Drugs Lead Multiple Sclerosis Drugs Market
High Unmet Need and Rich Pipeline to Expand MS Market
Sales Dip Inevitable for Current Therapies
Tough Times Ahead for Betaseron
Competitive Landscape

Table 7. Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)

D. The ALS Market in Review
The ALS Epidemiology
Market Overview
Sanofi-aventis – The ALS Drugs Market Leader
E. The Huntington's Market in Review
The HD Epidemiology
Market Outlook
F. Neuropathic Pain Market in Review
Market Overview
G. Prion Disease
Disease Origin

3.FUTURE THERAPIES

Alzheimer’s Disease
Select Pipeline Drugs for Alzheimer’s Disease
Parkinson’s Disease
Select Pipeline Drugs for Parkinson’s Disease
Huntington’s Disease
Select Pipeline Drugs for Treatment of Huntington’s Disease
Multiple Sclerosis
Oral Pipeline Drugs to Alter Market Dynamics in MS Therapies
Select Pipeline Drugs for Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Select Pipeline Drugs for Amyotrophic Lateral Sclerosis

4.NEURODEGENERATIVE DISEASES OVERVIEW

Neurodegeneration
An Overview of Factors that Link Neurodegenerative Diseases
Genetics
Intracellular Mechanisms
Protein Degradation Pathways
Mitochondrial Dysfunction
Axonal Transport
Programmed Cell Death
An Overview of Select Major Neurodegenerative Diseases
Alzheimer's Disease
Definition
Cause
Diagnoses
Prevention
Treatment
Anti-AD Drug Classes and Approved Products
Parkinson’s Disease
Definition
Cause
Diagnosis
Therapeutic Treatment
List of Drugs Available for the Treatment of Parkinson’s Disease
Surgical Intervention
Multiple Sclerosis
Definition
Types of Multiple Sclerosis

Table 8. Prevalence of Different Types of Multiple Sclerosis (includes corresponding Graph/Chart)

Etiology
Pathology
Treatment
List of Approved Multiple Sclerosis Drugs
Huntington’s Disease
Definition
Prognosis
The Three Stages of HD
Symptoms and Signs
List of Physical, Psychiatric and Cognitive Symptoms in Huntington’s Disease
Diagnosis
Treatment
Amyotrophic Lateral Sclerosis (ALS)
Definition
Types of ALS
Familial ALS
Sporadic ALS
Guamanian ALS
Etiology
Symptoms
Diagnosis
Treatment

5.AN OVERVIEW OF NEURODEGENERATIVE DRUGS FOR SELECT DISEASES

Neurodegenerative Drugs for Alzheimer’s Disease
NMDA Receptor Antagonists (NMDARA)
Memantine
Cholinesterase Inhibitors (ChEIs)
Donepezil (Aricept)
Rivastigmine (Exelon)
Galantamine Hydrobromide (Razadyne)
Tacrine (Cognex)
Other Alternatives
Vitamin E
Estrogen Therapy
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Gingko Biloba
Neurodegenerative Drugs for Parkinson’s Disease
Dopaminergic Agents
Levodopa/Carbidopa
Dopamine Agonists
Bromocriptine/Parlodel
Ropinirole/Requip
Pramipexole/Mirapex
Cabergoline/Dostinex
Apomorphine/Apokyn
Other PD Drugs
COMT Inhibitors
MAO-B Inhibitors
Dopamine Amplifiers
Anticholinergics
Neurodegenerative Drugs for Huntington’s Disease
Tetrabenazine
Others
Neurodegenerative Drugs for Multiple Sclerosis
Interferon Drugs
Beta Interferon Drugs for the Treatment of Multiple Sclerosis
Non-Interferon Drugs
Non-Interferon Drugs for the Treatment of Multiple Sclerosis
Neurodegenerative Drugs for Amyotrophic Lateral Sclerosis
Rilutek
Symptomatic Treatment

6.NEURODEGENERATIVE RESEARCH

Neurologix’s Non-dopamine Gene Therapy for PD
Cell Cure’s Cell Replacement Therapy for PD
Researches Developing Neuroprotective Agent for PD
UT Southwestern Researchers Study New Compound for HD
UCLA Scientists Identify Molecular Switch Capable of Blocking HD
Repligen Reports Detection of HDAC 3 Drug Target for Friedreich's Ataxia (US)
Tel Aviv University Reports Stem Cell Cure for Neurodegeneration (Israel)
Cambridge Researchers Develop Novel Drug Targets for HD
Emory Research Team Develops First Transgenic Monkey Model of HD
KeyNeurotek Pharma Discloses Molecular Pathomechanism of HD Mutation
Researchers Identify New Gene for ALS
Q Therapeutics and Johns Hopkins Research Team to Study GRPs in ALS Model
ALS TDI and CSC Collaborate to Study Stem Cells Use in ALS Treatment
Allen Institute and ALS TDI to Conduct ALS Study
Life Technologies to Develop Neurodegenerative Disease Models
Neuralstem and University of Michigan Collaborate for ALS Research
ALS TDI and MDA Collaborate for ALS Drug Discovery

7.SELECT CLINICAL TRIALS

Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
Medivation's Dimebon Fails to Meet End Points in Phase III Trial
QR Pharma Annuls Phenserine Production
Neurologix Begins Phase II Studies for Parkinson's Disease Treatment (US)
Biovail and ACADIA Complete Phase II Clinical Trials for Pimavanserin (Canada, US)
Merck Serono Announces Encouraging Phase III Results of Oral Mylinax
Alnylam and Medtronic Present New Preclinical Data on ALN-HTT
NeuroSearch Presents ACR16 as Novel Huntington’s Disease Therapy
Eli Lilly Launches Two Phase-III Trials for Solanezumab(i) Worldwide (US)
Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod
CytRx Initiates Phase II/III Clinical Trial for Arimoclomol
Synosia Therapeutics Starts Stage-I Clinical Trial for SYN-120 (Switzerland)
H. Lundbeck Begins Phase-I Clinical Tests for Lu 02-750 (Denmark)
Anavex Life Sciences Selects FORENAP Pharma EURL for ANAVEX 2-73 Phase-I Clinical Tests (Switzerland)
Bayer Schering Pharma Completes Stage-II Trials for BAY 94-9172 (Germany)
Newron and Merck Serono Start Second Round of Phase III Tests for Safinamide (Italy)
Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon Beta-1a
ExonHit Therapeutics Completes Phase-II Clinical Study for EHT 0202 (France)
Kyowa Hakko Kirin to Start Phase-III Clinical Trials for Istradefylline in Japan
Medtronic and Alnylam Pharma Report Pre-Clinical Results of ALN-HTT (US)
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Treatment
NeuroSearch Begins Critical Phase III Program with ACR16
Avicena to Proceeds with Phase III Trial of HD-02
Knopp Neurosciences Commences Phase II Study of KNS- 760704
Maas Biolab SBIR Initiates Phase II for Cyclosporin
MediciNova Announces Phase II Clinical Trial Results of MN-166
Avicena Proceeds to NIH Sponsored Phase III Trial for HD-02
EnVivo Pharmaceuticals Progresses on Major HDACi Program
NeuroSearch Files CTA in Europe to Begin Clinical Phase III Program with ACR16

8.PRODUCT INTRODUCTIONS/ APPROVALS/ DEVELOPMENTS

Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple Sclerosis
Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
Accera Introduces Axona™
Eisai Receives Approval for Aricept®
Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of MS
Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of MS
Novartis Obtains FDA Approval for Extavia
ArmaGen Develops IgG-Decoy Receptor Fusion Protein (US)
Knopp’s KNS-760704 Receives EC Orphan Designation
NeuroSearch Receives EMEA Approval for Huntexil™ Brand Name (Europe)
Cambridge Labs Receives Spanish Marketing Approval for Tetrabenazine
ArmaGen Technologies Secures Orphan Drug Designation for AGT-181 from FDA (US)
Raptor Pharmaceuticals Receives FDA Orphan Drug Designation for Cysteamine
Elan and Biogen Receive Health Canada Approval for MS Use of Tysabri™
Exelon Patch Wins EU Approval for Alzheimer's Treatment
Isis Pharma Receives Orphan Drug Designation for ISIS333611

9.RECENT INDUSTRY ACTIVITY

Lundbeck Acquires LifeHealth
StemCells Acquires Stem Cell Sciences
Oryzon Takes Over Crystax Pharmaceuticals
JANSSEN Acquires Elan’s Alzheimer’s Immunotherapy Program
Hisamitsu Takes Over Noven Pharmaceuticals
Lundbeck Takes Over Ovation Pharmaceuticals
Valeant Pharmaceuticals Takes Over Dow Pharmaceutical Sciences
Genzyme Acquires Assets of Targeted Genetics Corporation
Merck Takes Over Insmed’s Follow-on Biologics Assets
NeuroSearch Reacquires Global Rights to ACR16
Biovail Acquires Worldwide Rights to Tetrabenazine
Raptor Pharmaceuticals Merges with TorreyPines
iZumi Bio Merges with Pierian; Forms iPierian, Inc.
Cell Genesys Merges with BioSante Pharmaceuticals
CeNeRx BioPharma Secures Marketing and Development Rights for CXB909
Laureate Pharma and ZZ Biotech Ink Agreement
QxPharma Limited Signs Agreement with Patheon
Cambridge Labs Signs New Agreements to Market Xenazine® in North America
Shire and UCB Ink Agreement
NeuroNova and Genentech Signs Agreement for VEGF Use in ALS Treatment
Biovail to Acquire North American Rights to Fipamezole from Santhera
Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane
KineMed Collaborates with Bristol-Myers Squibb
Vitae Pharmaceuticals Collaborates with Boehringer Ingelheim
Insmed Inks Deal with IDIS to Organize NPPs for IPLEX™
Genzyme Corp. and Bayer HealthCare Sign Agreement
CHDI Foundation Inks Agreement with AMRI for Drug Discovery
Addex Pharmaceuticals Inks Licensing Agreement with Merck
Acccera Sets Up Neuera Pharmaceuticals
Evotec Inks Research Agreement with Biogen Idec
ALS TDI and Asklepios to Develop ALS Therapy Delivery Alternatives
Evotec Extends Collaboration with Boehringer Ingelheim
Neuralstem Collaborates to Develop Neural Stem Cell Therapies
Eisai and Pfizer Ink Agreement
BioAdvance Invests in TREVENTIS Corp.
AstraZeneca Announces Milestone Payments to Targacept for AZD3480 Program
Suven Life Sciences Secures Two Patents in the US
Eisai Terminates Contract with Nitto Denko Corporation
MJFF Awards Grants to Targacept
Metabolic Solutions Receives Grant from Alzheimer's Drug Discovery Foundation
Medical Research Council and Wellcome Trust to Fund Neurodegeneration Research
Biovail Acquires Prestwick Pharmaceuticals
GlaxoSmithKline Acquires Sirtris Pharmaceuticals
Newron Pharmaceuticals Acquires Hunter-Fleming
SYGNIS Pharma Purchases Amnestix
Proximagen Neuroscience Acquires Cambridge Biotechnology
Teva Acquires Barr Pharmaceuticals
Eisai Acquires MGI Pharma
Ovation Pharmaceuticals Acquires License to Commercialize Xenazine® in the US
Targeted Genetics Acquires Rights to the siRNA Development Program
Insmed Obtains Royalty-Free Global Rights for IPLEX™
Pfizer and Serenex Ink Agreement
Dr. Reddy's Laboratories Inks Agreement with Sygnis Pharma
Cambridge Labs Inks and Renews Agreements in Multiple Nations
CHDI Inked Collaboration Agreements with Galapagos
Power3 Medical Products and StemTroniX Sign Letter of Intent
ALS Therapy Development Institute and Allen Institute Ink Agreement
Yissum Inks Licensing Agreement with Eucalyptus
GlaxoSmithKline Biologicals Enters into Licensing Agreement with AFFiRiS
Neurologix and Aegera Therapeutics Ink Licensing Agreement
Neurobiological Inks Licensing Agreement with BIAR
Raptor Pharma Forms Collaboration with CHU d'Angers for Phase II Trial
Amorfix Completes Research Partnership with Biogen Idec
Apitope Raises Financing for Developing Multiple Sclerosis Compound
Pipex Pharmaceuticals Changes Corporate Name to Adeona Pharmaceuticals
MethylGene Terminates Collaboration Agreement with EnVivo Pharmaceuticals
Varinel Receives Fund from Alzheimer's Drug Discovery Foundation
PharmatrophiX Receives Grants from Alzheimer's Drug Discovery Foundation
Eisai Acquires Morphotek
Transition Therapeutics Acquires NeuroMedix
Merz Licenses Anti-Alzheimer’s Drug Technology from TAU
Intellect Neurosciences Inks Agreement with CHDI Foundation to Evaluate Potential of OXIGONTM
Intellect Signs Licensing Agreement with Immuno- Biological Laboratories
Boehringer Ingelheim Signs R&D Agreement with Ablynx
Evotec Teams Up with Boehringer Ingelheim
Siemens Medical Signs Partnership Agreement with Wyeth
Pipex Pharma Signs Agreement for Evaluation of COPREXA
Digilab Receives Notice of Allowance for New Alzheimer's Biomarker
Pfizer Joins Forces with Genizon for AD
Avicena Teams Up with NINDS for Phase III Trial of PD-02
QSV and Artielle Sign Contract to Produce RTL-1000 (To be added to Canada)
ALS TDI Selects Microbix to Manufacture Adenoviruses
Maas BiolAB Receives SBIR Grant for ALS Study

10.FOCUS ON SELECT GLOBAL PLAYERS

Amarin Corporation PLC (Ireland)
AstraZeneca PLC (UK)
Avanir Pharmaceuticals, Inc. (US)
Avigen, Inc. (US)
Bayer Schering Pharma AG (Germany)
Boehringer Ingelheim GmbH (Germany)
Biogen Idec Inc. (US)
Bristol-Myers Squibb Co. (USA)
Biovail Corporation (Canada)
Ceregene, Inc. (US)
Eisai, Inc. (USA)
Elan Pharmaceuticals (US)
Eli Lilly and Company (USA)
Forest Laboratories, Inc. (US)
GlaxoSmithKline PLC (UK)
H. Lundbeck A/S (Denmark)
Merz Pharmaceuticals GMBH (Germany)
Merck Serono SA (Switzerland)
Mitsubishi Tanabe Pharma Corporation (Japan)
Neurologix, Inc. (US)
NeuroSearch A/S (Denmark)
Novartis AG (Switzerland)
Pfizer, Inc. (US)
Sanofi-aventis S.A (France)
Shire Pharmaceuticals Group PLC (UK)
Teva Pharmaceutical Industries Limited (Israel)
Valeant Pharmaceuticals International (US)
Wyeth Pharmaceuticals, Inc. (US)

11.GLOBAL MARKET PERSPECTIVE

Analytics by Geographic Region

Table 9. World Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 10. World 10-Year Perspective for Neurodegenerative Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

Analytics by Disease Type

Table 11. World Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Disease Type – Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 12. World 10-Year Perspective for Neurodegenerative Drugs by Disease Type – Percentage Breakdown of Dollar Sales for Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Current & Future Analysis
AD Market Overview
Approval of Cholinesterase Inhibitors for MCI to Drive Market
Status of AD Drugs
Prevalence

Table 13. US Prevalence of Alzheimer’s Disease for 2005-2010 (includes corresponding Graph/Chart)

PD Market Overview
Levodopa/Carbidopa on Declining Spree
Patent Expiry Status
Patent Expiry Status of Parkinson’s Disease Drugs in the US
Prevalence
Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market
Clinical Trials
Product Launches
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 14. US Recent Past, Current and Future Analysis for Neurodegenerative Drugs Market – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2.EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Alzheimer’s and Parkinson’s Prevalence in Europe

Table 15. European Alzheimer’s Disease Prevalence by Country/Region: Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe in Thousands For Years 2001 through 2010 (includes corresponding Graph/Chart)
Table 16. European Parkinson’s Disease Prevalence by Country/Region: Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)
Table 17. Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

Low Penetration to Fuel Growth in European MS DMDs Market
Clinical Trials
Product Launches/Approvals
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 18. European Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Country/ Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 19. European 10-Year Perspective for Neurodegenerative Drugs by Country/Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart)

3.REST OF WORLD

A. MARKET ANALYSIS

Current & Future Analysis
Canada – High Prevalence Rates for Multiple Sclerosis

Table 20. Multiple Sclerosis Prevalence in Canada For Years 2001 through 2010 (includes corresponding Graph/Chart)

Incidence of Multiple Sclerosis on the Rise in India

Table 21. Multiple Sclerosis Prevalence in India For Years 2001 through 2010 (includes corresponding Graph/Chart)

Alzheimer’s and Parkinson’s Prevalence in Canada

Table 22. Alzheimer’s and Parkinson’s Diseases and Multiple Sclerosis Prevalence in Canada For Years 2001 through 2010 (includes corresponding Graph/Chart)

Alzheimer’s and Parkinson’s Prevalence in Japan

Table 23. Alzheimer’s and Parkinson’s Diseases Prevalence in Japan for Years 2001 through 2010 (includes corresponding Graph/Chart)

Alzheimer’s Prevalence in Asia-Pacific

Table 24. Alzheimer’s Disease Prevalence in Asia-Pacific by Country: Number of Patients for Australia, India, Philippines and Rest of Asia-Pacific in Thousands For Years 2001 through 2010 (includes corresponding Graph/Chart)

Clinical Trials
Research Studies/Other Developments
Product Launches/Approvals
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 25. Rest of World Recent Past, Current and Future Analysis for Neurodegenerative Drugs Market – Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 165 (including Divisions/Subsidiaries - 190)
Region/CountryPlayers
The United States93
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Skip to top


Neurodegenerative Diseases: World Drug Market 2011-2026 US$ 2,325.00 Nov, 2010 · 182 pages
Drug and Device Combination (2009 - 2014) US$ 5,650.00 Jul, 2009 · 238 pages
CNS Generic Drugs: Prospects and Opportunities to 2012 US$ 1,740.00 Apr, 2008 · 290 pages

Ask Your Question

Neurodegenerative Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: